Avicenna.AI | AI Radiology

Author: Stéphanie BELLAVIA

ConcertAI’s TeraRecon partners with Avicenna.AI for AI-driven chest care coordination.

CAMBRIDGE, Mass., 01/11/2023 – ConcertAI’s TeraRecon, a leader in advanced visualization and AI Clinical SaaS, is pleased to announce an expanded collaboration with Avicenna.AI, a specialist in medical imaging AI. Together, they will provide global solutions that leverage artificial intelligence to enhance care coordination and improve patient triage for individuals afflicted with pulmonary embolism (PE) and aortic dissection (AD). This collaboration aims to expedite clinical decision-making and optimize patient care for these critical medical conditions.
Diagnosing and coordinating care for patients facing PE and AD pose significant hurdles. Avicenna.AI has FDA approval for its algorithms, tailored for PE and both Type A and Type B AD, which will seamlessly integrate into the Eureka Clinical AI platform. This integration aims to streamline identification of these conditions, thus empowering multidisciplinary patient care coordination. Upon detecting a PE or AD, the Eureka Clinical AI platform will rapidly notify each provider’s desktop or mobile device, delivering dynamic imaging and comprehensive patient information. Additionally, the aortic module offering will grant access to imaging and workflows supporting coordinated care for patients with abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), rupture, stenosis, and transection, alongside the AD algorithm. Likewise, the PE algorithm will be accessible through the Eureka Clinical AI platform’s PE module.
The inclusion of AI-powered workflows via the Eureka Clinical AI platform is anticipated to significantly reduce the time it takes a physician to diagnose these potentially life threating conditions to treatment by facilitating more informed treatment decisions across health systems.
Through the incorporation of Avicenna’s PE and AD solutions, coupled with the existing CINA-iPE on the Eureka Clinical AI platform for the EU, TeraRecon is positioned to offer enhanced pulmonary and aortic solutions to its global clientele of approximately 1,900 customers.
“We are dedicated to expanding the Eureka Clinical AI ecosystem with impactful AI solutions that support our clinicians and care providers,” said Dan McSweeney, President of TeraRecon. “Avicenna’s solutions play a crucial role in fulfilling this commitment by broadening access to essential triage capabilities through our scalable Eureka Clinical AI platform.”
Avicenna.AI specializes in providing healthcare AI solutions that utilize deep learning to identify, detect, and quantify life-threatening pathologies from CT images. By employing a blend of deep learning and machine learning technologies, the company’s solutions autonomously detect and prioritize emergency cases within seconds, assess their severity, and promptly notify radiologists.
“We are excited to empower TeraRecon users worldwide with our groundbreaking AI-driven solutions for the care coordination of pulmonary embolism and aortic dissection,” said Cyril Di Grandi, Chief Executive Officer of Avicenna.AI. “Our aim is to expedite an optimal medical response within a short timeframe and enhance patient care. We eagerly anticipate extending the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond.”
Eureka Clinical AI stands as the foremost AI SaaS imaging interpretation and clinical decision augmentation solution from ConcertAI’s TeraRecon. Distinguished as the industry’s most widely deployed platform, it uniquely accommodates third-party AI algorithms, facilitating consolidated management of all AI interpretation solutions with seamless PACS integrations. Multi-specialty care teams can swiftly access results and receive mobile alerts to confirm AI findings, ensuring optimal and timely patient interventions, management, and coordinated care delivery.
To learn more about the Eureka Clinical AI platform, its capabilities, and algorithms spanning neurology, radiology, cardiology, oncology, and more, visit: https://www.terarecon.com/artificial-intelligence.
About TeraRecon: Serving approximately 1,900 clinical sites globally, TeraRecon, a ConcertAI company, is a Best in KLAS solution provider for AI-empowered radiology, oncology, cardiology, neurology, and vascular surgery. Awarded the KLAS Category Leader for Advanced Visualization, TeraRecon solutions are independent of any one manufacturer’s imaging equipment or PACS, allowing a single, unified, and simplified clinical workflow that can improve efficiencies and deliver actionable physician-guided insights. For more information, visit us at www.terarecon.com
About ConcertAI: ConcertAI is the leader in Real-World Evidence (RWE) and AI technology solutions for life sciences and health care. Our mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies. For more information, visit us at http://www.concertai.com or follow us on LinkedIn.
About Avicenna.AI: Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and to enhance clinicians’ workflow. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning. www.avicenna.ai

07/11/2023
ConcertAI’s TeraRecon and Avicenna.AI Partner on AI for Incidental Pulmonary Embolism

Medical imaging AI companies collaborate to offer CINA-iPE on TeraRecon’s Eureka Clinical AI platform.
Cambridge, Mass., March 13, 2023 – ConcertAI’s TeraRecon, the advanced visualization and AI Clinical SaaS category leader, today announced a partnership to offer medical imaging AI specialist Avicenna.AI‘s CINA-iPE solution detecting the presence of incidental pulmonary embolisms as part of TeraRecon’s Eureka Clinical AI solution. Eureka Clinical AI and Intuition are KLAS top-rated solutions for clinical AI and advanced visualization.
Incidental pulmonary embolism is a frequent finding on routine CT scans of the chest, but only 25% of incidental emboli are reported at the initial interpretation. CINA-iPE is a CE-marked AI tool that analyzes images from CT scans and detects the presence of incidental pulmonary embolism immediately and with great immdiat consistency and accuracy. Delayed and missed findings are some of the most serious problems in diagnostic imaging, and incidental pulmonary embolism is a significant cause of mortality in the cancer patient population.
“We are committed to expanding the Eureka Clinical AI ecosystem with meaningful AI solutions to support our clinicians and care providers. Avicenna’s incidental pulmonary embolism detection algorithm is just one example of this commitment. This unique solution expands access to this critical diagnostic capability via our scalable Eureka Clinical AI platform,” said Dan McSweeney, President of TeraRecon.
Avicenna.AI provides healthcare AI solutions that use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. Using a combination of deep learning and machine learning technologies, the company’s solutions automatically detect and prioritize emergency cases within seconds, assess them for severity, and then seamlessly alert radiologists.
“We are delighted to empower the wide community of TeraRecon users with our innovative incidental pulmonary embolism AI algorithm. This global partnership brings healthcare providers closer to a more systematic reporting and treatment of life-threatening pulmonary emboli,” said Cyril Di Grandi, co-founder and CEO of Avicenna.AI.
Eureka Clinical AI is the leading AI SaaS imaging interpretation and clinical decision augmentation solution from ConcertAI’s TeraRecon. As the industry’s most broadly deployed platform, it is unique in that it is open to third-party AI algorithms, allowing consolidated management of all AI interpretation solutions with seamless PACS integrations. Multi-specialty care teams can see results and receive mobile alerts to confirm AI findings, ensuring optimal and timely patient interventions, management and coordinated care delivery.
Learn more about the Eureka Clinical AI platform capabilities and algorithms that span across neurology, radiology, cardiology, oncology, and more: https://www.terarecon.com/artificial-intelligence
About ConcertAI: ConcertAI is the leader in AI Saas Technologies for clinical research and clinical care and Real-World Evidence (RWE) solutions. Our mission is to accelerate insights and biomedical innovations, thereby improving outcomes for patients. For more information, visit us at www.concertai.com
About TeraRecon: Serving ~1,900 clinical sites globally, TeraRecon, a ConcertAI company, is a Best in KLAS solution provider for AI-empowered radiology, oncology, cardiology, neurology, and vascular surgery. Awarded the KLAS Category Leader for Advanced Visualization, TeraRecon solutions are independent of any one manufacturer’s imaging equipment or PACS system, allowing a single, unified, and simplified clinical workflow that can improve efficiencies and deliver actionable physician-guided insights. For more information, visit us at www.terarecon.com
About Avicenna.AI
Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and to enhance clinicians’ workflow. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning. www.avicenna.ai

15/03/2023
Avicenna.AI launches AI solution for incidental pulmonary embolism detection

Medical imaging company to introduce CINA-iPE – the first tool in its new AI suite for incidental findings – at ECR 2023.
Marseille, FRANCE – February 22, 2023 – Medical imaging AI specialist Avicenna.AI today announced the launch of CINA-iPE, a CE-marked AI tool that analyzes images from CT scans for the presence of incidental pulmonary embolism. CINA-iPE is the first tool in CINA Incidental, a new suite of medical imaging solutions from Avicenna.AI that detect unsuspected pathologies on CT scans.
Avicenna.AI will demonstrate CINA-iPE for the first time at the European Congress of Radiology, March 1 – 5, 2023.
Incidental pulmonary embolism is a frequent finding on routine CT scans of the chest, but only 25% of incidental emboli are reported at the initial interpretation. Delayed and missed findings are some of the most serious problems in diagnostic imaging, and incidental pulmonary embolism is a significant cause of mortality in the cancer patient population.
CINA Incidental sits alongside the company’s existing suite, CINA ER, which includes a range of FDA-cleared and CE-Marked tools for neurovascular and thoraco-abdominal emergencies. All of Avicenna.AI’s AI tools are seamlessly integrated within clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.
“If pathologies are visible on a CT scan, the technology now exists to detect them – helping clinicians reduce time-to-treatment and save lives,” said Cyril Di Grandi, co-founder, and CEO of Avicenna.AI. “Our CINA Incidental suite helps healthcare professionals detect incidental findings in patients receiving imaging for entirely different health conditions, improving patient care and outcomes. The launch of CINA-iPE is the first step in a new direction for Avicenna.AI. Pulmonary embolism is a dangerous, life-threatening condition, and with CINA-iPE we hope to increase the number of patients identified with incidental PE and help improve their outcomes.”
Avicenna.AI provides healthcare AI solutions that use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. Using a combination of deep learning and machine learning technologies, the company’s solutions automatically detect and prioritize emergency cases within seconds, and assess them for severity, before seamlessly alerting radiologists.
ECR 2023 delegates can find out more at the Avicenna.AI booth (AI-25).

22/02/2023
Incepto Collaborates with Avicenna.AI to improve stroke management in Europe

Paris, France. February 13th, 2023 – Incepto, distributor, and co-creator of artificial intelligence (AI) solutions applied to medical imaging, signs a partnership with Avicenna.AI, developer of AI solutions for Radiology, and enriches its platform with new solutions for neurovascular pathologies such as stroke. All of these solutions are CE-cleared, and two are FDA marked. These solutions are now available via the Incepto platform in France, Germany, Italy, Spain, Portugal and Switzerland.
Worldwide, stroke affects between 12 and 15 million people each year*, meaning that 1 person out of 6 will suffer from a stroke in their lifetime. Despite improvements in primary care prevention and treatment, stroke is a devastating disease in the 21st century. Stroke is a leading cause of long-term disability and the second leading cause of death, with one death every 6 seconds worldwide*.
Three new artificial intelligence solutions for emergency care of neurovascular pathologies
CINA-ICH is a triage tool for detecting and prioritizing cases with traumatic brain injuries and hemorrhagic stroke on non-enhanced (non-contrast) head CT images. Five types of intracranial hemorrhages are detected: intraparenchymal, intraventricular, subarachnoid, subdural and epidural.
CINA-LVO is an ischemic stroke triage tool designed to detect LVO of the anterior circulation (distal ICA, M1, or proximal M2) on CT angiographies of the head.
CINA-ASPECTS is a quantitative tool that provides an ASPECT score on a non-enhanced head CT Scan, indicated for patients with acute ischemic stroke with known middle cerebral or carotid artery occlusion.
All of these solutions constitute the CINA Head suite. They enable to quickly detect and interpret the images, to reduce diagnostic errors while facilitating decision-making for doctors, and finally, to improve the quality of care for patients.
In stroke care, every minute counts. These new AI solutions reduce the time-to-treatment and improve patient outcomes and the quality of post-operative life.
About Incepto
Created in 2018, Incepto is the first European platform for artificial intelligence solutions applied to medical imaging. With a hundred clinics equipped with their AI solutions and already more than 100,000 patients monitored every month, Incepto’s mission is twofold: to help doctors identify the most efficient solutions and put them at their service, while co-creating new applications with them, adapted to their specific needs. Incepto’s ambition is to assist doctors on a daily basis in improving the accuracy of diagnoses, the treatment process and the quality of patient care. https://incepto-medical.com
About Avicenna.AI
Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and to enhance clinicians’ workflow. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning. www.avicenna.ai

16/02/2023
Avicenna.AI Lands Series A Funding to Fuel Global Growth, Bringing Total Investment to $10 Million

Medical imaging AI company brings total investment to $10 million and targets global growth.
Marseille, FRANCE – February 8, 2023 – Medical imaging AI specialist Avicenna.AI today announced it has secured a Series A funding round, bringing aggregated investment in the company close to $10 million. The round was backed by existing investors Innovacom and CEMAG Invest.
The new funds will be used to scale up deployment of Avicenna.AI’s solutions across the world and to diversify the company’s offering into new areas of medicine.
“Last year was pivotal for Avicenna.AI, with huge growth in the deployment of our solutions around the world, and very positive feedback from our partners and users alike,” said Cyril Di Grandi, co-founder, and CEO of Avicenna.AI. “We have created the conditions to accelerate the extension of our portfolio within our emergency suite but also outside our initial scope. We have finally obtained the first patents that will allow us to consolidate our position as a leader in the field with a disruptive approach to the use of deep learning in therapeutic decision-making. This new investment reflects the continued confidence of our investors and signifies our readiness to become a dominant force in healthcare AI.”
Avicenna.AI provides healthcare AI solutions that use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. Using a combination of deep learning and machine learning technologies, the company’s solutions automatically detect and prioritize emergency cases within seconds, and assess them for severity, before seamlessly alerting radiologists.
Avicenna.AI’s unique business model is based on an asset-light, R&D powerhouse expertise, generating rapid business growth potential through already signed commercial partnerships with leading market actors in the US, Europe and Asia.
In a successful year for the company, 2022 saw Avicenna’s AI solutions rolled out to more than 140 hospitals in 14 countries across three continents. The company is now ready to scale up in 2023, and expects to deploy at least 30 new sites every month this year.
In parallel, Avicenna’s R&D efforts will add to the four FDA and six CE mark approvals already awarded to its products. The company’s FDA-cleared and CE-Marked tools for neurovascular and thoraco-abdominal pathologies are seamlessly integrated within the clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.
About Avicenna.AI
Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and to enhance clinicians’ workflow. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning. www.avicenna.ai
About Innovacom
Innovacom is a pioneer in innovation capital in France. Since 1988, it has invested nearly €1 billion, supported more than 300 digital and high-tech startups, participated in more than 20 IPOs and completed more than 150 industrial divestments.
The team, which benefits from a long experience in high-tech, has contributed to several recent successes in multiple sectors (telco, healthcare, mobilityì, energy…) and has a solid track-record including unicorns like Heptagon or Soitec.
Today, Innovacom supports innovative industrial projects and high-potential disruptive technologies by providing financing, advice and support. Its association with the Turenne Group has givenì birth to one of the leading independent private equity firms in France with a platform of €1.5 billion under management. With offices in Paris and Marseille, Innovacom Gestion is licensed by the Autorité des Marchés Financiers.
About Cemag Invest
Cemag Invest is a family office dedicated to healthcare and technology, with a focus on adding value to patients. Cemag Invest has notably invested in Wandercraft, Diabeloop, and alongside innovacom in Aryballe Technologies.

08/02/2023
Avicenna.AI partners with CARPL.ai on AI to detect life-threatening conditions

Avicenna.AI’s advanced AI detection tools are now available via the CARPL platform.
Marseille, FRANCE – November 22, 2022 – Medical imaging AI specialist Avicenna.AI today
announced a distribution agreement with CARPL.ai, a technology platform that enables service provider-oriented testing, validation and deployment of AI applications to healthcare providers.
As the number of AI applications coming into the clinical realm increases, it can be challenging for healthcare providers to access, assess and then integrate these solutions into their clinical workflows. CARPL bridges this gap by acting as an intermediary platform for the development, testing, distribution and deployment of AI applications.
The CARPL platform now includes Avicenna.AI’s range of CINA solutions for neurovascular and thoraco-abdominal pathologies, which use deep learning to identify, detect and quantify life-threatening pathologies from CT medical images. The FDA-cleared and CE-Marked tools are seamlessly integrated within the clinical workflow, automatically triggering and reporting algorithm results through the systems already used by radiologists.
Using a combination of deep learning and machine learning technologies, the CINA solutions
automatically detect and prioritize cases within seconds, and assess them for severity, seamlessly alerting radiologists within their existing systems and workflow.
“CARPL.ai specializes in driving the adoption of radiology AI solutions into clinical workflows and improves patient outcomes, by enabling and empowering healthcare service providers to discover, explore, and validate cutting-edge AI and then deploy it in their environment with confidence,” said Dr. Vidur Mahajan, Chief Executive Officer of CARPL.ai. “When it comes to stroke care and other life-threatening conditions, we are delighted to now be able to offer Avicenna’s portfolio as a comprehensive solution to our customers.”
“We’re excited to partner with a leading platform like CARPL, which has a strong presence in key new markets for us, including Australia, Brazil and India,” said Cyril Di Grandi, co-founder, and CEO of Avicenna.AI. “They are also deployed in many large hospital environments, which is exactly what our solutions are designed for – delivering faster detection of critical conditions, improving radiology efficiency and supporting better patient outcomes.”
Avicenna.AI will be attending RSNA 2022, November 27 – 30. To book a meeting, email
contact@avicenna.Ai.
About Avicenna.AI
Founded in 2018, Avicenna.AI develops medical imaging AI solutions for highly prevalent pathologies. The company uses artificial intelligence and deep learning to optimize many of a radiologist’s manual tasks. Its CINA products leverage deep learning algorithms to identify acute abnormalities and support emergency room triage. Avicenna.AI is co-founded by Cyril Di Grandi, who previously co-founded and successfully sold Olea Medical, and Dr. Peter Chang, a radiologist and internationally recognized expert in AI and deep learning.
www.avicenna.ai
About CARPL.ai
CARPL is an end-to-end technology platform for the development, testing, distribution and
deployment of medical imaging AI applications in clinical workflows. Used by some of the world’s top AI researchers and health systems, it connects AI applications and healthcare providers helping improve access, affordability, and quality of medical care.
www.carpl.ai

22/11/2022
Avicenna.AI collaborates with deepc to revolutionize Stroke Patient Care
Marseille, FRANCE – September, 27, 2022. Medical imaging specialist Avicenna.AI today announced a groundbreaking partnership with the MedTech company deepc, offering one of the leading radiology AI platforms (deepcOS), to give healthcare providers access to their stroke suite.
This move facilitates a step change in patient management for stroke, enabling rapid treatment decisions by combining a uniquely comprehensive stroke management technology with a platform that seamlessly integrates into radiologist’s clinical workflow.
Every Second Counts.
Avicenna.AI’s stroke suite gives radiologists exactly the tools they need to rapidly and automatically identify, triage, and assess patients, enabling faster decision-making and saving lives.
Avicenna.AI’s CINA stroke suite provides a full range of tools powered by deep learning to automatically identify acute abnormalities and support the emergency imaging department. It comprises two FDA-cleared, CE-marked tools for automatic triage, and one CE-marked quantification tool:
CINA-LVO is a triage tool that instantly flags suspected Large Vessel Occlusion (LVO) on CT angiography. Given that every minute of untreated LVO means two million neurons are lost, early diagnosis is critical.
Real-time trial tool CINA-ICH highlights suspected acute Intracranial Hemorrhage (ICH) on CT scans, efficiently prioritizing cases, drastically reducing the time to treatment. ICH affects over two million people worldwide with a 40-50% mortality rate within one month, so accurate early
detection and treatment are vital.
CINA-ASPECTS is a quantification tool that automatically measures an ASPECT Score to assess ischemic changes in stroke. CINA-ASPECTS enables faster, more consistent, and more precise interpretations for assessing acute ischemic stroke.
To reach its potential, this technology needs to be available to those who need it. That’s where deepc comes in, by creating a cutting-edge AI ecosystem providing radiologists instant access to AI-powered technologies. The platform is changing the way AI is adopted by integrating directly into the clinical workflow. Avicenna.AI’s full stroke suite is now available through the platform, meaning more physicians and patients can benefit from its tools than ever before.
John Moulden, Chief Commercial Officer at deepc: “Our companies bring a challenger mindset to this amazing partnership, and together we offer truly revolutionary technology to healthcare providers and their radiology departments. Looking forward to working together with Avicenna.AI!“
Olivier Fuseri, Sales Manager at Avicenna.AI: “We are thrilled that our solutions for Stroke are integrated in such a groundbreaking platform as deepcOS. Together we are committed to transform the future of radiology through our combined technologies.”
23/09/2022
Avicenna.AI partners UpCare for innovative value-based solutions to Canadian health providers

Toronto & Marseille – July 27^th , 2021 –Medical imaging AI specialist Avicenna.AI today announced a partnership with UpCare Partners & Associates to distribute, deliver and implement a fully integrated stroke detection AI solution for any PACS Platform in Canada.
With this partnership, Avicenna provides UpCare with its FDA-approved CINA Head triage AI solution for neurovascular emergencies, which detects two of the leading causes of stroke – intracranial hemorrhage (ICH) and large vessel occlusion (LVO) – from CT-scan imaging.
Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.
CINA’s ICH detection capability was validated using data from 814 cases conducted at more than 250 imaging centers across the United States, with 96% accuracy, 91.4% sensitivity and 97.5% specificity. The product’s LVO detection capability was validated based on 476 cases, with 97.7% accuracy 97.9% sensitivity and 97.6% specificity.
“Canada is a Leading Country in the world of Neuroscience, the partnership will enrich physicians’ resources for accessing and qualifying Stroke events and ICH seamlessly in a record time; we are always looking to provide our customers with enhanced and expanded imaging capabilities” said Benoit Sai, Co-Founder & CCO, UpCare Partners & Associates. “By adding Avicenna’ proven and validated solutions to our Neuroscience ecosystem, Canadian healthcare providers have access to innovative automated advanced brain imaging technology, allowing them to deliver better patient care.”
Cyril Di Grandi, co-founder and CEO, Avicenna.AI, said, “Our partnership with a Canadian distributor focussing on ecosystems approach toward the continuum of care in the field of neurosciences combined with expertise in medical imaging, medical devices and ai like UpCare Inc is a testament to the excellent accuracy, sensitivity and specificity data that has been gathered during our validation phase. We look forward to working with our new partner to bring the benefits of our AI-powered stroke triage solution to the emergency room and beyond in Canada.”
About UpCare Partners & Associates
Founded in 2019, UpCare Partners & Associates, a Canadian MedTech Company, is the gateway to the Canadian market for start-ups and international OEM. The company provides the best expertise in each field by committing special attention and a focussed approach to your product on a Pan Canada basis. In this challenging time for Healthcare Institutions UpCare Partners & Associates works with its partners on Value Based Solutions for the best Patient Outcome and Continuum of Care. www.upcarepartners.com

27/07/2021
Viz.ai and Avicenna.AI Launch AI Care for Pulmonary Embolism & Aortic Disease

San Francisco and Paris – July 15, 2021 – Viz.ai, the world leader in AI-driven intelligent care coordination has partnered with Avicenna.AI, a global leader in artificial intelligence solutions, to enable intelligent care coordination and improve patient triage of patients suffering from pulmonary embolism (PE) and aortic disease (AD). The collaboration will pave the way for faster clinical decision making and care for patients suffering from these two life threatening conditions.
Diagnosis and care coordination of patients suffering from PE and aortic disease can be challenging. Avicenna.AI’s FDA-approved algorithms for PE and Type A and Type B aortic dissection (AD), leveraged on the Viz intelligent care coordination platform, will empower multidisciplinary care teams to easily coordinate patient care by sending notifications paired with dynamic imaging and detailed patient information to each provider’s desktop or mobile device as soon as a PE or an aortic dissection is detected. As part of Viz.ai’s commercial aortic module offering, access to imaging and workflows supporting the coordination of care for patients with abdominal aortic aneurysm (AAA), thoracic aortic aneurysm (TAA), rupture, stenosis and transection will be available in addition to the AD algorithm. Similarly, the PE algorithm will be available on Viz.ai’s commercial PE module.
“The addition of AI powered workflows should decrease the time from diagnosis to treatment and help to coordinate care for patients suffering from life-threatening PE and aortic disease, as it has in the treatment of ischemic stroke. It will help to facilitate faster and easier treatment decisions across health systems, and this should improve outcomes for patients,” said Dr. Richard Saxon, interventional radiologist Tri-City Medical Center.
The Viz Platform is clinically proven and validated by Medicare, which reimburses hospitals directly via a New Technology Add-On Payment for Viz LVO, the time-saving ischemic stroke product. Pairing team alerts enhanced by AI with high-fidelity mobile image viewing, patient information and full-stack secure communication enables multidisciplinary teams to make faster treatment decisions for patients. The result increases access to care and improves outcomes for patients.
“We are proud to become a trusted partner of Viz.ai, who is committed to giving access to high-standard healthcare systems worldwide. Thanks to our AI-based solutions, we hope to facilitate an optimal medical response within a short time frame and improve patient care. We look forward to bringing the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond,” said Cyril Di Grandi, chief executive officer of Avicenna.AI.
PE is a potentially deadly form of venous thromboembolic disease, a common cause of cardiovascular death, and is associated with multiple inherited and acquired risk factors affecting hundreds of thousands of people every year globally. PE occurs when a blood clot gets lodged in an artery in the lung, blocking blood flow to part of the lung. Similar to PE, aortic disease is potentially deadly and can require urgent surgical intervention to prevent death.
“We’re delighted to partner with Avicenna to bring intelligent care coordination to the peripheral vascular and vascular fields. This will form part of a broader Viz.AI platform, where any patient with life threatening diseases can benefit from AI powered triage, fast mobile communication and synchronized care coordination,” said Dr. Chris Mansi, Viz.ai CEO and co-founder. “This partnership will bring the advantages of artificial intelligence to more patients and help hospitals achieve better clinical outcomes.”
About Viz.ai, Inc.
Viz.ai is the leader in AI-driven intelligent care coordination. Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment, improve access to care, and increase the speed of diffusion of medical innovation. Viz.ai’s clinically validated platform leverages advanced deep learning to communicate time-sensitive information to specialists who can more quickly and easily make treatment decisions for the patient. In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, the first-ever computer-aided triage and notification software. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis. A third FDA clearance was granted in 2020 for Viz ICH, which uses AI to automatically detect suspected intracranial hemorrhage on CT imaging. In 2020, CMS granted Viz.ai the first New Technology Add-on Payment (NTAP) for artificial intelligence software for Viz LVO.
Viz.ai is located in San Francisco and Tel Aviv and backed by leading Silicon Valley investors, including Kleiner Perkins, Google Ventures, Greenoaks, CRV, Threshold Ventures, Innovation Endeavors, Susa Ventures, Scale Venture Partners and Insight Partners.
Click here and find out more about Viz.ai.

15/07/2021
Avicenna.AI Joins Nuance AI Marketplace, Offering Cutting-Edge Solutions for Diagnostic Imaging

Marseille, France – 29th June, 2021 – Avicenna.AI today announced that their FDA-cleared applications for neurovascular emergencies, CINA-ICH & CINA–LVO, are available on the Nuance® AI Marketplace, the first and largest portal with one-stop access to a wide range of AI diagnostic models from within the industry’s most widely used radiology reporting platform.
CINA offers radiologists an unparalleled solution for triaging patients with positive impact on high occurrence life-threatening pathologies. CINA-ICH and CINA-LVO automatically detect and prioritize acute intracranial hemorrhage and large vessel occlusion cases within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.
The Nuance AI Marketplace functions like an app store dedicated to radiology. It gives algorithm developers consolidated, at-scale access to users of Nuance PowerScribe™, the radiology reporting system trusted by approximately 80 percent of U.S. radiologists across more than 9,000 connected healthcare facilities. Radiologists can discover, test, and use AI models from within their familiar Nuance PowerScribe reporting and workflow orchestration solutions to increase reporting efficiency and quality, and to help care teams improve patient outcomes and healthcare costs. A built-in feedback channel lets users share real-world results with developers for model refinement and post-market surveillance. Hospital systems benefit with simplified purchasing and metrics showing AI usage, costs, and performance.
“We are glad to partner with a global partner such as Nuance who shares our same values to put patient care at the core of their business. Together we are committed to transforming medical imaging by empowering radiologists in their daily tasks. Thanks to this partnership and our combined solutions, we aim to advance the future of healthcare,” said Cyril Di Grandi, Chief Executive Officer and co-founder of Avicenna.AI.

29/06/2021